Lifeboat Foundation

The human body is an incredible machine. It is impossible to determine which is the essential body part for sustaining life — because there is no single indispensable part. If your heart stops beating, you will die. If your lungs stop working, your brain — and thus all of your cells — will eventually die. Without a stomach or intestines you cannot acquire nutrients and you will die. All parts are critical for optimal function, for sustaining life.

Synthetic biology as a field is no different. There are those that supply DNA — arguably the critical building block for every single synthetic biology application. There are those that automate and scale components of the design-build-test cycle to enable innovation to effect change in meaningful timelines. But when all of those parts come together with a single goal, the power of synthetic biology reaches new levels.

Such potential is exactly what Arzeda — through a collaboration with TeselaGen, Twist Bioscience, and Labcyte — has brought to us. Each company, a giant in its own right, provides an essential, needed component to an elegant, efficient workflow that can best be described as a “DNA assembly line” for more rapid, efficient protein design and production. The companies’ products work seamlessly: Twist produces the DNA fragments needed to make protein-expressing plasmids, Labcyte’s acoustic liquid handler (the Echo 525) facilitates rapid DNA assembly, and TeselaGen’s DNA assembly design and laboratory automation software connects the two, designing plasmids and ordering the necessary sequences from Twist while generating worklists for the Echo to execute.

New blood test could predict your risk of early death!

Age-related changes to the signals sent and received by our cells travelling via the bloodstream are one of the hallmarks of aging. A team of researchers, including Drs. Irina and Michael Conboy, has published the results of a new study suggesting that rejuvenation might be achieved by the calibration of these signals found in the blood [1].

The search for rejuvenation

The Conboys had done earlier research in joining of the circulatory systems between young and old animals, a process known as parabiosis, and they showed that tissue aging was not a one-way street and could be rapidly reversed in a matter of weeks, given access to the beneficial signaling from the younger animal [2].

Why the rush? It now costs $2.6 billion, by one estimate, to get a new drug to market, and pipelines are only getting slower and more expensive. There’s hope—and hype—that AI could help chip away at that figure by reducing the time and labor before a drug starts clinical trials. The idea is that the same techniques used to generate realistic deepfakes and deftly play Go might be able to decipher the complex rules of drug design and generate molecules from scratch.

Insilico Medicine is among several startups trying to harness artificial intelligence to speed to development of drugs.

Scientists have identified the mechanism that lets geckos regrow severed limbs, and they may get it to work in humans.

We will soon learn if a much-hyped, rapamycin-like drug can boost the immune response by targeting how the body ages.

A simple treatment to stave off the health problems of old age could be available in five to 12 years. Here’s how it would work.

A group of DARPA-funded scientists associated with Elon Musk say they’ve invented a new way to “rapidly implant” brain electrodes into rats — and their “sewing machine” implantation system could facilitate the creation of a mind-reading brain-computer interface, as first reported by Bloomberg.

“Although more research is needed to refine the overall interface system and better integrate its components, these developments may ultimately open the possibility of bundling next-generation robotics, AI software, and electronics to create alternatives to present-day neurosurgical techniques,” DARPA biotech director Justin Sanchez told Bloomberg.

Non-addictive painkillers from scorpion venom? Bring them on!